A Phase IV Clinical Trial of Patients with Solid Tumors Receiving Lenograstim as Primary Prophylaxis for Chemotherapy-Induced Neutropenia, in a Docetaxel-Based Regimen

Table 2

Incidence of neutropenia, febrile neutropenia, and other adverse effects.

	All grades, 𝑛 (%)	Grade 3-4, 𝑛 (%)
Neutropenia	137 (34.8)	64 (16.2)
Febrile neutropenia	6 (1.5)	6 (1.5)
Anaemia	214 (54.3)	5 (1.3)
Anorexia	49 (12.4)	2 (0.5)
Asthenia	183 (46.4)	16 (4.1)
Myalgia	182 (46.2)	20 (5.1)
Oral mucositis	147 (37.3)	6 (1.5)
Nail discolouration	91 (23.1)	—
Nail ridging	35 (8.9)	—
Nail loss	14 (3.6)	—

The percentage is calculated out of the 394, the total number of patients in the study’s cohort.